BCG With or Without Gefitinib in Treating Patients With High-Risk Bladder Cancer

NCT00352079 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

41

Enrollment

NETWORK

Sponsor class

Stopped terminated due to poor accrual

Conditions

Bladder Cancer

Interventions

BIOLOGICAL: BCG vaccine
DRUG: gefitinib
PROCEDURE: quality-of-life assessment

Sponsor

NCIC Clinical Trials Group